IMC Chicago’s Procept Biorobotics PRCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.09M Buy
48,400
+9,400
+24% +$235K ﹤0.01% 3751
2026
Q1
$975K Buy
39,000
+8,400
+27% +$237K ﹤0.01% 3315
2025
Q4
$963K Sell
30,600
-23,700
-44% -$786K ﹤0.01% 3004
2025
Q3
$1.94M Buy
54,300
+35,900
+195% +$1.64M ﹤0.01% 2248
2025
Q2
$1.06M Sell
18,400
-8,200
-31% -$464K ﹤0.01% 2436
2025
Q1
$1.55M Buy
26,600
+8,000
+43% +$546K ﹤0.01% 1967
2024
Q4
$1.5M Buy
18,600
+3,500
+23% +$299K ﹤0.01% 2081
2024
Q3
$1.21M Buy
+15,100
New +$1.07M ﹤0.01% 1957

Other funds holding PRCT

IMC Chicago's PRCT Position: Q2 2026 in Review

IMC Chicago increased its Procept Biorobotics (PRCT) stake by 23% in Q2 2026, buying an estimated $115K and bringing the position to 24,495 shares worth $553K. The position accounts for ﹤0.01% of the portfolio, ranked #4528.

IMC Chicago first reported a position in PRCT in Q4 2025 and has held it in 3 quarters since. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • IMC Chicago held 24,495 shares of Procept Biorobotics worth $553K as of Q2 2026.
  • IMC Chicago bought 4,598 Procept Biorobotics shares in Q2 2026, an estimated $115K.
  • Procept Biorobotics made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #4528 holding.
  • IMC Chicago first reported a position in Procept Biorobotics in Q4 2025 and has held it in 3 quarters since.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.